This list includes research results that have significantly impacted the standards of care provided to patients and/or the major paradigms on which research for the disease, injury, or condition are based.
Clicking on the link will take you to the project's Abstract.
Breast Cancer Research Program
- Dr. Dennis Slamon, University of California, Los Angeles: Herceptin®, a monoclonal antibody that targets the HER2 receptor, is part of standard-of-care treatment regimens for HER2+ early-stage and metastatic breast cancers.
- Dr. Kathryn Verbanac, East Carolina University: Sentinel Lymph Node Biopsy is a standard-of-care diagnostic/prognostic technique that enables clinicians to determine tumor staging and if more extensive lymph node surgery is necessary.
- Dr. Susan Neuhausen, University of Utah: Discovery of the BRCA2 617delT mutation, one of the BRCA gene mutations that significantly increase an individual's risk for breast and ovarian cancers, led to development of a commercialized genetic screening test for BRCA1/BRCA2 mutations.
Neurofibromatosis Research Program
- Dr. Long-Sheng Chang, Research Institute at Nationwide Children's Hospital: Generation of a Mouse Model for Schwannomatosis.
Ovarian Cancer Research Program
- Dr. Zhen Zhang, Johns Hopkins University: OVA1, an in vitro diagnostic multivariate index test, is the only FDA-approved blood test to help determine if an ovarian mass is malignant or benign prior to surgery, facilitating surgical planning and identifying patients for referral to a gynecologic oncologist.
Prostate Cancer Research Program
- The Prostate Cancer Clinical Trials Consortium (PCCTC), Coordinating Center Principal Investigator, Dr. Howard Scher, Memorial Sloan-Kettering Cancer Center: ZYTIGA® (abiraterone acetate), which blocks androgen production, has become standard-of-care for men with docetaxel-resistant, metastatic castration-resistant prostate cancer. The PCCTC was responsible for the rapid early-phase clinical testing of ZYTIGA prior to FDA approval in 2011.
- Dr. Evan Keller, University of Michigan: XGEVA® (denosumab), a monoclonal antibody used for the prevention of bone loss and fracture during prostate cancer treatment and currently under testing for the prevention of prostate cancer metastasis, based on Dr. Keller's discoveries on the activities of a regulator of bone resorption, RANKL.
Spinal Cord Injury Research Program
- Dr. Damien Pearse, Miami, University of, School of Medicine: Schwann Cell Implantation for SCI repair.